At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.
In Brief
A Phase 3 clinical trial evaluating Vitamin A, Candidate Plasmodium falciparum malaria vaccine, and 2 other interventions for Malaria and Malaria Vaccines. Completed, enrolled 699 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6 months at the first vaccination.
Study Details
Timeline
Interventions
Oral administration of Vitamin A (1 dose)
Intramuscular administration of SB257049 vaccine (4 doses)
Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
Intramuscular injection of a yellow fever (YF) vaccine (1 dose)